Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3013 Structurally-Optimized Peptide VMT-Alpha-NET Enhances the Efficacy of SSTR2-Targeted Alpha-Particle Therapy for Neuroendocrine Tumors

Introduction: 203Pb/212Pb is a promising theranostics pair for SSTR2-targeted alpha-particle therapy for neuroendocrine tumors (NETs). The development of SSTR2-targeted peptides that are optimized for the Pb isotopes has the potential to improve performance.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Lee D, Li M, Baumhover N, Liu D, Sagastume E,

Keywords: prrt, VMT-alpha-NET, 203Pb/212Pb theranostics,

#3001 Early Response Assessment for Prediction of Overall Survival after Peptide Receptor Radionuclide Therapy

Introduction: PRRT response assessment is performed using RECIST, yet functional assessment using 68Ga-DOTATATE PET/CT and plasma CgA might give additional information about prediction of overall survival (OS).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Huizing D, Aalbersberg E, Versleijen M, Tesselaar M, Walraven I,

Keywords: PRRT, RECIST, 68Ga-DOTATATE PET/CT, response,

#3000 Patients with Somatostatin Receptor Type 2-Negative Neuroendocrine Tumors Have Sustained Inferior Survival Rates in a Propensity Score-Matched Analysis

Introduction: Sufficient expression of somatostatin receptor type 2 (SST2) in neuroendocrine tumors (NETs) is crucial for treatment with unlabelled somatostatin analogues (SSAs), or peptide receptor radionuclide therapy (PRRT) using radio-labelled SSAs. Impaired prognosis has been described for SST2-negative NET patients, however studies comparing matched SST2-positive and -negative subjects are missing.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Refardt J

Authors: Refardt J, Zandee W, Brabander T, Feelders R, Franssen G,

Keywords: somatostatin receptor type 2, outcome, propensity score analysis, survival,

#2990 Pitfalls in Glucagon-Like Peptide-1 Receptor Imaging

Introduction: Physiological pancreatico-duodenal DOTA-Exendin-4 uptake in the Brunner’s glands of the proximal duodenum occurs in Glucagon-like peptide-1 receptor (GLP-1R) imaging and is a known potential pitfall.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Antwi K

Authors: Antwi K, Hepprich M, Reubi J, Christ E, Wild D,

Keywords: insulinoma, GLP-1R imaging,

#2988 Epigenetic Treatment with Histone Deacetylase Inhibitor Enhances Uptake of [111In]In-DOTA-TATE by Increased SST2 Expression on Neuroendocrine Tumor Cells

Introduction: The somatostatin-2 receptor (SST2) is a target for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NETs). By using epigenetic drugs, which can regulate gene transcription, PRRT efficacy may be further improved due to enhanced SST2 expression.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Klomp I

Authors: Klomp I, Dalm S, van Koetsveld P, Dogan-Oruç F, de Jong M,

Keywords: neuroendocrine tumors, bon-1, epigenetic, histone, histone deacetylase inhibitor, HDACi, upregulation, reversibility, somatostatin receptor-2, somatostatin,

Abstract Submissions in 2023

Abstract submissions for 2023 will open in September 2022!


The 20th Annual ENETS Conference in 2023 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.


Participants of the ENETS Conferences in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.